In the title compound, C 17 H 17 N 3 O 3 S, the cyclopentane ring is disordered over two sets of sites with an occupancy ratio of 0.775 (8):0.225 (8) for the affected atoms. The thiazolidinyl ring is planar (r.m.s. deviation = 0.024 Å ) and forms a dihedral angle of 65.13 (8) with the attached phenyl ring. The molecular packing is stabilized by C-HÁ Á ÁO and C-HÁ Á Á interactions, forming a three-dimensional structure.
Related literature
For biological properties of thiazole-containing compounds, see: Quiroga et al. (2002) ; Hutchinson et al. (2002) ; Hargrave et al. (1983) ; Patt et al. (1992) ; Sharma et al. (2009) ; Jaen et al. (1990) ; Tsuji & Ishikawa (1994) ; Bell et al. (1995) : Ergenc et al. (1999) ; Carter et al. (1999) ; Badorc et al. (1997) ; Rudolph et al. (2001) . Table 1 Hydrogen-bond geometry (Å , ) .
Experimental 2.1. Crystal data
Cg4 is the centroid of the C9-C14 ring. Data collection: CrysAlis PRO (Agilent, 2014); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS2014 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL2014 (Sheldrick, 2015; molecular graphics: ORTEP-3 for Windows (Farrugia, 2012) ; software used to prepare material for publication: PLATON (Spek, 2009 ).
S1. Comment
Thiazoles are important class of heterocyclic compounds, found in many potent biologically active molecules such as sulfathiazol (antimicrobial drug), Ritonavir (antiretroviral drug), Abafungin (antifungal drug), with trade name Abasol cream, and Bleomycine and Tiazofurin (antineoplastic drug). It has been noted over the years that interesting biological activities (Quiroga et al., 2002; Hutchinson et al., 2002) were associated with thiazole derivatives. Applications of thiazoles were found in drug development for the treatment of allergies (Hargrave et al., 1983) , hypertension (Patt et al., 1992) , inflammation (Sharma et al., 2009) , schizophrenia (Jaen et al., 1990) , bacteria infection (Tsuji & Ishikawa, 1994) , HIV infection (Bell et al., 1995) , hypnotics (Ergenc et al., 1999) and for the treatment of pain (Carter et al., 1999) , as fibrinogen receptor antagonists with antithrombotic activity (Badorc et al., 1997) and as new inhibitors of bacterial DNA gyrase B (Rudolph et al., 2001) . In this context we report in this study the synthesis and crystal structure of the title compound.
The molecular structure of the title compound is shown in Fig. 1 In the crystal, C-H···O and C-H···π interactions stabilize the molecular packing, forming a three-dimensional network, Fig. 2 
S2. Experimental
A mixture of 2-cyclopentylidene-N-phenylhydrazinecarbothioamide (1 mmol, 233 mg) and dimethyl but-2-ynedioate (1 mmol, 142 mg) in ethylacetate (10 ml) was stirred and refluxed at 350 K. The reaction progress was monitored by TLC until completion. On cooling, a solid yellow product was precipitated, filtered off, dried under vacuum and recrystallized from ethanol to afford yellow crystals.
S3. Refinement
All H atoms were positioned geometrically and constrained to ride on their parent atoms (C-H = 0.93-0.97 Å) with U iso (H) = 1.2-1.5U eq (C). The cyclopentyl group was partially disordered over two positions with refined site-occupancies of 0.775 (8) The molecular packing viewed down a axis. The C-H···O interactions are shown as dotted lines with non-participating H atoms omitted for clarity.
Methyl (2Z)-2-[(2Z)-2-(2-cyclopentylidenehydrazin-1-ylidene)-4-oxo-3-phenyl-1,3-thiazolidin-5-ylidene]ethanoate
Crystal data ) is used only for calculating -R-factor-obs etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (

